High-Dose Intravenous Immunoglobulin May Reduce Latent HIV Reservoir in Resting CD4+ Cells, Study Suggests (February 10, 2009)
A five-day course of high-dose intravenous immunoglobulin appears to somehow activate replication-competent HIV in the resting CD4+ cells of patients on HAART, ultimately leading to a reduction in those patients' latent HIV reservoirs, according to the results of a nine-patient study presented by Magnus Gisslén, M.D., Ph.D.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The Next Generation of Boosters: Promising Data on Potential Alternatives to Ritonavir (February 9, 2009)
Brian Kearney, Pharm.D., of Gilead Sciences Inc., and Robert Guttendorf, Ph.D., of Sequoia Pharmaceuticals discuss encouraging findings from early human trials on a pair of pharmacokinetic enhancers whose utility could potentially extend far beyond protease inhibitor boosting.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Biotechnology Company to Launch Trial of New HIV/AIDS Treatment That Would Target DNA (February 4, 2009)
The treatment involves taking a sample of an HIV-person's CD4 cells and disrupting the CCR5 gene, which is the molecule HIV usually attaches to before infecting the cell. The idea is that, when those modified CD4 cells are put back into an HIVer's body, they'll multiply into an HIV-resistant army of immune cells.
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
E-Mail
Glossary
Share
